Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9–15 months old Nepalese infants
Authors:
- 2 September 2022
- Vol. 40 (40) , 5828-5834
Abstract
No abstract availableKeywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1115556)
This publication has 21 references indexed in Scilit:
- Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 StudyClinical Infectious Diseases, 2015
- Typhoid feverThe Lancet, 2015
- Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trialsThe Lancet Infectious Diseases, 2014
- Salmonella Typhi in the Democratic Republic of the Congo: Fluoroquinolone Decreased Susceptibility on the RisePLOS Neglected Tropical Diseases, 2012
- Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010Journal of Global Health, 2012
- Fluoroquinolone-Resistant Typhoid, South AfricaEmerging Infectious Diseases, 2010
- Global Trends in Typhoid and Paratyphoid FeverClinical Infectious Diseases, 2010
- a study of typhoid fever in five Asian countries: disease burden and implications for controlsBulletin of the World Health Organization, 2008
- Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in IndiaJournal of Antimicrobial Chemotherapy, 2006
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001